US based Generex Biotechnology has received new patents in Canada and Argentina for the process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration

The Canadian Intellectual Property Office has granted a patent for the process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration. The National Institute of Industrial Property of Argentina has granted the company a new patent for the process and formulation claims to a mixed liposome pharmaceutical formulation.

Generex is engaged in the research and development of drug delivery systems and technologies. The company currently holds an aggregate of 125 patents worldwide (21 of which are United States Patents) and has an aggregate of 90 patent applications pending in various jurisdictions.

The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.